COMSTOCK RESOURCES INC (CRK)       11.895  -0.04 (-0.38%)

11.895  -0.04 (-0.38%)

US2057683029 - Common Stock


Fundamental Rating

6

Taking everything into account, CRK scores 6 out of 10 in our fundamental rating. CRK was compared to 389 industry peers in the Oil, Gas & Consumable Fuels industry. While CRK is still in line with the averages on profitability rating, there are some concerns on its financial health. CRK has both an excellent growth and valuation score. This means it is growing and it is still cheap. This is a rare combination!




Profitability

Profitability Rating

5

CRK has a Return On Assets of 15.15%. This is better than the industry average of 12.18%.
CRK's Return On Equity of 47.16% is amongst the best of the industry. CRK does better than the industry average Return On Equity of 25.65%.

CRK has a good Piotroski-F score of 7.00. This indicates a good health and good profitability for CRK.
CRK has a Profit Margin of 21.53%. This is below the industry average of 25.51%.
VS Industry

ROA (15.15%) VS Industry: 62% outperformed.

0.06
1,189.87

ROE (47.16%) VS Industry: 80% outperformed.

0.24
5,310.48

Profit Margin (21.53%) VS Industry: 38% outperformed.

0.07
268.29

Valuation

Valuation Rating

8

With a Price/Earnings Ratio of 3.89, the valuation of CRK can be described as very cheap.
CRK's Price/Earning Ratio is a bit cheaper than the industry average which is at 6.49.
The Forward Price/Earnings Ratio of 2.46 indicates a rather cheap valuation of CRK.
The low PEG Ratio, which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.

Compared to an average Enterprise Value to EBITDA ratio of 4.12, CRK is valued rather cheaply. On top of this, CRK has a better ratio than 93% of the companies listed in the same industry.
When comparing the current price to the book value of CRK, we can conclude it is valued correctly. It is trading at 1.55 times its book value.
When comparing the price book ratio of CRK to the average industry price book ratio of 1.60, CRK is valued in line with its industry peers.
VS Industry

Price/Earnings (3.89) VS Industry: 78% outperformed.

1,200.13
0.07

Price/Book (1.55) VS Industry: 52% outperformed.

3,299.06
0.05

Enterprise Value/ EBITDA (1.66) VS Industry: 93% outperformed.

242.51
0.29

Growth

Growth Rating

9

The Earnings Per Share has grown by an impressive 222.11% over the past year.
CRK is expected to show a strong growth in Earnings Per Share. In the coming 5 years, the EPS will grow by 34.17% yearly.
CRK shows a strong growth in Revenue. In the last year, the Revenue has grown by 167.35%.

Measured over the past 5 years, CRK shows a very strong growth in Revenue. The Revenue has been growing by 60.15% on average per year.
Based on estimates for the next 5 years, CRK will show a very strong growth in Revenue. The Revenue will grow by 21.00% on average per year.
The Revenue growth is decreasing: in the next 5 years the growth will be less than in the last years.

PastFuture
5Y3Y1Y1Y2Y3Y5Y
EPSN/A N/A 222.11% 210.92% 102.37% 53.96% 34.17%
Revenue60.15% 68% 167.35% 72.16% 34.84% 21% N/A

Health

Health Rating

3

CRK has a good Piotroski-F score of 7.00. This indicates a good health and good profitability for CRK.
CRK has an Altman-Z score of 2.68. This is not the best score and indicates that CRK is in the grey zone with still only limited risk for bankruptcy at the moment.
CRK has a Altman-Z score comparable to the industry average, which is at 2.14.
A Current Ratio of 0.65 indicates that CRK may have some problems paying its short term obligations.

When comparing the Current Ratio of CRK to the average industry Current Ratio of 1.09, CRK is less able to pay its short term obligations than its industry peers.
CRK has a Quick Ratio of 0.65. This is a bad value and indicates that CRK is not financially healthy enough and could expect problems in meeting its short term obligations.
Compared to an average industry Quick Ratio of 0.94, CRK is worse placed to pay its short term obligations than its industry peers.
Compared to an average industry Debt to Equity Ratio of 0.30, CRK is requires more financing than its industry peers. 84% of its industry peers have a better Debt to Equity Ratio.
VS Industry

Debt/Equity (1.26) VS Industry: 16% outperformed.

31.33
0.00

Quick Ratio (0.65) VS Industry: 30% outperformed.

0.00
297.28

Current Ratio (0.65) VS Industry: 26% outperformed.

0.00
297.28

Altman-Z (2.68) VS Industry: 58% outperformed.

-283,883.16
1,166.96

Dividend

Dividend Rating

4

CRK's Dividend Yield is rather good when compared to the S&P500 average which is at 2.41.
2.07% of the earnings are spent on dividend by CRK. This is a low number and sustainable payout ratio.
CRK has a Yearly Dividend Yield of 3.95%. Purely for dividend investing, there may be better candidates out there.

The stock price of CRK dropped by -35.21% in the last 3 months. With lower prices the dividend yield is higher, but it may be a sign investors do not trust the long term dividend.
CRK's Dividend Yield is slightly below the industry average, which is at 5.56.
CRK is new to the dividend game and has less than 3 years of track record.
VS Industry

Dividend Yield (3.95%) VS Industry: 36% outperformed.

0.34
64.51

COMSTOCK RESOURCES INC11.895

NYSE:CRK (2/2/2023, 8:52:09 AM)-0.04 (-0.38%)

Chartmill FA Rating
GICS Sector Energy
GICS IndustryGroup Energy
GICS Industry Oil, Gas & Consumable Fuels
Earnings (Last) 11-01 2022-11-01/amc Earnings (Next) 02-13 2023-02-13
Inst Owners 35.73% Inst Owner Change 0.3%
Ins Owners 1.87% Ins Owner Change 18.53%
Market Cap 2.78B Analysts 68.75
Price Target 20.15 (69.4%)

Dividend
Dividend Yield 3.95% Dividend Growth N/A
DP 2.07% Ex-Date N/A

Surprises & Revisions
EPS beat(2) 1 Avg EPS beat(2) 2.06%
Min EPS beat(2) -0.25% Max EPS beat(2) 4.36%
EPS beat(4) 2 Avg EPS beat(4) -3.85%
Min EPS beat(4) -21.76% Max EPS beat(4) 4.36%
Revenue beat(2) 2 Avg Revenue beat(2) 106.35%
Min Revenue beat(2) 51.01% Max Revenue beat(2) 161.69%
Revenue beat(4) 4 Avg Revenue beat(4) 70.04%
Min Revenue beat(4) 30.55% Max Revenue beat(4) 161.69%
PT rev (1m) -5.2% PT rev (3m) -13.1%
EPS NQ rev (1m) 0% EPS NQ rev (3m) -18.16%
EPS NY rev (1m) 0% EPS NY rev (3m) -1.63%
Revenue NQ rev (1m) 0% Revenue NQ rev (3m) -5.08%
Revenue NY rev (1m) 0% Revenue NY rev (3m) 3.3%

Valuation
Industry RankSector Rank
PE 3.89
Fwd PE 2.46
P/S 0.71
P/FCF 5.61
P/OCF 1.92
P/B 1.55
P/tB 1.91
EV/EBITDA 1.66
EPS(TTM) 3.06 EY 25.73%
EPS(NY) 4.83 Fwd EY 40.63%
FCF(TTM) 2.12 FCFY 17.82%
OCF(TTM) 6.18 OCFY 51.97%
SpS 16.81 BVpS 7.68
TBVpS 6.24 PEG (NY) 0.02
PEG (5Y) N/A

Profitability
Industry RankSector Rank
ROA 15.15%
ROE 47.16%
ROIC 45.06%
ROICexc 45.45%
ROICexgc 49.16%
OM 65.2%
PM 21.53%
GM 81.08%
ROICexgc(3y) 10.61% ROICexcg growth 3Y 42.17%
ROICexcg growth 5Y N/A ROICexc(3y) 9.73%
ROICexc growth 3Y 47.46% ROICexc growth 5Y N/A
OM growth 3Y 11.41% OM growth 5Y N/A
PM growth 3Y N/A PM growth 5Y N/A
GM growth 3Y 2.05% GM growth 5Y 6.77%
F-Score 7 Asset Turnover 0.7

Health
Industry RankSector Rank
Debt/Equity 1.26
Debt/FCF 4.56
Debt/EBITDA 0.75
Cap/Depr 204.16%
Profit Quality 58.55%
Current Ratio 0.65
Quick Ratio 0.65
Altman-Z 2.68
F-Score 7 WACC 11.69%
ROIC/WACC 4.21 Cap/Depr(3y) 148.36%
Cap/Depr(5y) 170.67% Profit Quality(3y) N/A
Profit Quality(5y) N/A

Growth
EPS 1Y 222.11% EPS 3Y N/A
EPS 5Y N/A EPS growth Q2Q 247.06%
EPS Next Y 210.92% EPS Next 2Y 102.37%
EPS Next 3Y 53.96% EPS Next 5Y 34.17%
Revenue growth 1Y 167.35% Revenue growth 3Y 68%
Revenue growth 5Y 60.15% Revenue growth Q2Q 132.8%
Revenue Next Year 72.16% Revenue Next 2Y 34.84%
Revenue Next 3Y 21% Revenue Next 5Y N/A
EBIT growth 1Y 263.67% EBIT growth 3Y 87.17%
EBIT growth 5Y N/A EBIT Next Year 131.29%
EBIT Next 3Y 38.78% EBIT Next 5Y N/A
FCF growth 1Y 938.68% FCF growth 3Y N/A
FCF growth 5Y N/A OCF growth 1Y 158.76%
OCF growth 3Y 65.94% OCF growth 5Y N/A

Fundamental Stock Screener Links

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Growth Stock Screener

Find more growth stocks the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA